Nature Communications (Mar 2022)

p16INK4A-deficiency predicts response to combined HER2 and CDK4/6 inhibition in HER2+ breast cancer brain metastases

  • Jing Ni,
  • Sheheryar Kabraji,
  • Shaozhen Xie,
  • Yanzhi Wang,
  • Peichen Pan,
  • Xiaofang He,
  • Zongming Liu,
  • Jose Palbo Leone,
  • Henry W. Long,
  • Myles A. Brown,
  • Eric P. Winer,
  • Deborah A. R. Dillon,
  • Nancy U. Lin,
  • Jean J. Zhao

DOI
https://doi.org/10.1038/s41467-022-29081-2
Journal volume & issue
Vol. 13, no. 1
pp. 1 – 8

Abstract

Read online

HER2+ breast cancer often develop brain metastases (BCBMs) that are difficult to treat. Here, the authors show that p16INK4A loss in BCBMs from HER2+ breast tumors results in resistance to the HER2 inhibitor Tucatinib, and that CDK4/6 inhibition can restore sensitivity to this drug.